newsfilter
← Latest News
Business Wire·

Gilead to Acquire All Remaining Rights to Potential First-in-Class Immunotherapy GS-1811 From Jounce Therapeutics

-- Agreement Covers Buyout of Remaining Financial Obligations for Anti-CCR8 Antibody in Development as a Potential Treatment for Solid Tumors -- Gilead Sciences, Inc. (NASDAQ:GILD) and Jounce Therapeutics, Inc.